Press releaseACCESS Newswire
IGC Pharma
IGC · NYSE American
$0.245+$0.003 (+1.24%)TodayMarket closed ·
Prev close $0.242
Latest news
- Press releaseACCESS Newswire
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026
- Press releaseACCESS Newswire
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure
- Press releaseACCESS Newswire
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
- Press releaseACCESS Newswire
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
- Press releaseACCESS Newswire
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow
- Press releaseACCESS Newswire
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
- Press releaseACCESS Newswire
IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow
- Press releaseACCESS Newswire
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis
- Press releaseACCESS Newswire
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
- News
'Trump Reclassifies State-Licensed Medical Marijuana As A Less-Dangerous Drug In A Historic Shift' - AP News
- NewsAvi Kapoor
Why ZIM Integrated Shipping Services Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Why MillerKnoll Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
- News
'Trump Expected To Sign An Order Moving To Reclassify Cannabis And Open Up Medical Potential' - NBC News
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
UPDATE: 'Medicare to Test Making CBD Treatment Available for Seniors' - Bloomberg News
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsMohd Haider
Massive 69.4% Surge for IGC Pharma in After-Hours Trading: Here's Why
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- NewsRishabh Mishra
US Stocks Likely To Open Higher, Continuing Record-Setting Advances: June Has Never Seen An All-Time High Since 1950, Highlights Expert
- NewsAvi Kapoor
Progress Software, Exicure And 3 Stocks To Watch Heading Into Monday
- News
Insights Ahead: IGC Pharma's Quarterly Earnings
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- NewsNina Zdinjak
Cannabinoid Drug For Agitation In Alzheimer's Yields Cognitive Improvements In Clinical Trial
- Press releaseBusiness Wire
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment
- News
'Newly Elected Republican Senate Majority Leader Opposes Marijuana Legalization, Rescheduling And Industry Banking Access' - Marijuana Moment
- News
"Legislative Committee In Ireland Calls For Marijuana Legalization And Decriminalization Of 'All Illicit Drugs'" - Marijuana Moment
- News
"Kamala Harris Says 'We Need To Legalize' Marijuana For First Time As Democratic Presidential Nominee" - Marijuana Moment
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
"National Agriculture Regulators Group Grapples With Intoxicating Hemp For The First Time; FDA's Norm Birenbaum Says Existing FDA Regulatory Frameworks 'Do Not Apply To Large Segments Of The Market, Like Inhalable Products, Where We Have Tremendous Concerns'" - Cannabis Wire
- Press releaseBusiness Wire
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
- Press releaseBusiness Wire
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
- News
The Analyst Verdict: IGC Pharma In The Eyes Of 4 Experts
- Press releaseBusiness Wire
IGC Announces Results of its 2024 Annual Stockholders Meeting
- Press releaseBusiness Wire
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease
- Press releaseBusiness Wire
IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist
- News
'Trump Endorsing Florida Marijuana Legalization Initiative Would 'Guarantee Victory,' Top Ally Roger Stone Says' - Marijuana Moment
- Press releaseBusiness Wire
IGC Pharma Reports First Quarter Fiscal 2025 Results
- Press releaseBusiness Wire
IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.